Blend Therapeutics, a 1-year-old pre-clinical biotech focused on oncology drugs, has raised $16 million in Series B financing and named the former head of Sunovion Pharmaceuticals as its new CEO.
The $16 million round was led by NanoDimension, and existing investors Flagship Ventures and New Enterprise Associates also took part.
{iframe}http://www.bizjournals.com/washington/blog/techflash/2012/12/blend-therapeutics-secures-16m-in-vc.html{/iframe}